"versionIdentifier","instanceType","rationale","uuid:ID","id"
"2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","95d92a27-6f4a-44cb-bc0a-a737881ba450","StudyVersion_1"
